Daniel George

Sep 30, 2024 | onclive.com | Daniel George

Daniel J. George, MD, medical oncologist, Eleanor Easley Distinguished Professor of Medicine, Duke University School of Medicine, professor of medicine, professor of surgery, Duke Cancer Institute, discusses the emerging potential use of lutetium Lu 177 vipivotide tetraxetan (Pluvicto) and other radioligand therapies earlier in the treatment paradigm and in novel combinations for patients with prostate cancer.

Apr 12, 2024 | hematologyandoncology.net | Sundhar Ramalingam |Daniel George |Michael Harrison

Overview• Brain metastasis in patients with metastatic renal cell carcinoma generally signifies a poor prognosis. • Surgical resection is an option for patients with a single metastasis and good extracranial disease control. Stereotactic radiosurgery is an option for patients with limited-volume brain metastasis, whereas patients with more widespread disease require whole-brain radiotherapy.

Feb 11, 2024 | nature.com | Himisha Beltran |Michael Morris |Daniel George |Andrew Armstrong

AbstractCALGB 90401 (Alliance) was a phase III trial of 1050 patients with metastatic castration-resistant prostate cancer (mCRPC) comparing docetaxel, prednisone, bevacizumab (DP+B) versus DP alone. While this trial did not show an improvement in overall survival (OS), there were improved intermediate outcomes suggesting that subsets of men may derive benefit from this combination.

Feb 6, 2024 | urotoday.com | Daniel George

Read the Full Video TranscriptZach Klaassen: Hi, I'm Dr. Zach Klaassen, a urologic oncologist in Augusta, Georgia at the Georgia Cancer Center. And we are here live in San Francisco at GU ASCO 2024, and I'm pleased to be joined by UroToday regular, Dr. Dan George. We're going to talk highlights today. Dr. George is from Duke Cancer Center in Durham, North Carolina. Thanks for joining us again, Dan. Daniel George: My pleasure, Zach. Zach Klaassen: So let's talk about BRCAAway.

Feb 6, 2024 | urotoday.com | Daniel George

Read the Full Video TranscriptZach Klaassen: Hi, I'm Dr. Zach Klaassen, a urologic oncologist in Augusta, Georgia at the Georgia Cancer Center. And we are here live in San Francisco at GU ASCO 2024, and I'm pleased to be joined by UroToday regular, Dr. Dan George. We're going to talk highlights today. Dr. George is from Duke Cancer Center in Durham, North Carolina. Thanks for joining us again, Dan. Daniel George: My pleasure, Zach. Zach Klaassen: So let's talk about BRCAAway.